Article Information
History
- March 23, 2021.
Article Versions
- You are currently viewing Version 1 of this article (March 23, 2021 - 16:36).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Prasanna Channathodiyil1,
- Anne Segonds-Pichon3,
- Paul D. Smith4,
- Simon J. Cook5 and
- Jonathan Houseley1,*
- 1Epigenetics Programme, Babraham Institute, Cambridge, UK
- 3Babraham Bioinformatics, Babraham Institute, Cambridge, UK
- 4Oncology R&D, AstraZeneca CRUK Cambridge Institute, Cambridge, UK
- 5Signalling programme, Babraham Institute, Cambridge, UK
- ↵*Corresponding author: jon.houseley{at}babraham.ac.uk
Posted March 23, 2021.
DNA replication during acute MEK inhibition drives acquisition of resistance through amplification of the BRAF oncogene
